UNC Lineberger Comprehensive Cancer Center
The UNC Lineberger Cancer Network (UNCLCN) partners with many communities across North Carolina to enhance cancer care and provide education to all North Carolinians. UNCLCN produces over 50 webinars and courses annually with leading oncologists, researchers, and healthcare providers from across the state and beyond. Our live webinars and online courses provide FREE CONTINUING EDUCATION CREDITS for Physicians (CME), Nurses (NCPD), Pharmacists (ACPE), Radiologic Technologist (ASRT), and Certified Tumor Registrars (CTR).
Please visit the UNCLCN Learning Portal to learn more and participate for in our free educational offerings. For questions or inquiries about contributing to our lectures, please contact unclcn@unc.edu.
Primary Brain Tumors: Gliomas - Astrocytomas
Disclaimer: On August 6, 2024, the FDA approved vorasidenib (Voranigo) for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.
Comments 0
Login to view comments.
Click here to Login
